Physician profile
Robert Dickerson Rehnke
NPI 1982739967
$6,058,592.08
in general payments reported to CMS, 2019-2025
10 companies · $4,421 in 2025
The $4,421 reported for 2025 was more than what 91% of Plastic Surgery providers received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $526K · 2020: $5.5M · 2021: $18K · 2022: $8,747 · 2023: $143 · 2024: $1,038 · 2025: $4,421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,825 · Honoraria: $1,050 · Food and Beverage: $727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,825.00 |
| Honoraria | $1,050.00 |
| Food and Beverage | $727.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $6,053,539.88 | 2019-2025 | Galaflex, Arista Ah Flexitip |
| Motiva USA, LLC | $2,770.03 | 2024-2025 | |
| Allergan, INC. | $1,172.07 | 2019-2022 | |
| Merz North America, INC. | $368.89 | 2019-2022 | |
| Becton, Dickinson and Company | $278.74 | 2021-2022 | |
| Abbvie INC. | $198.57 | 2023-2024 | |
| Mentor Worldwide LLC | $168.27 | 2019-2024 | Mentor Memorygel Resterilizable Gel Sizer |
| C. R. Bard, INC. & Subsidiaries | $59.00 | 2022 | |
| Tepha INC | $21.05 | 2020 | |
| Smith+Nephew, INC. | $15.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Rehnke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.